NEW YORK (GenomeWeb News) - Singulex said today that it has installed its Erenna biomarker-detection platform in Wyeth Research’s labs under its Erenna Technology Access Program.
The ETAP program includes the Erenna, which is used to detect and count single molecules, as well as customized immunoassay development services, reagents and software and other services. Singulex is working with Wyeth to develop immunoassays on the platform to accurately measure specific biomarkers in human blood.
Erenna is capable of measuring low levels and small changes of protein biomarkers in a variety of biological samples, the company said.
Wyeth is currently using Erenna to validate several assays “that should help us guide our clinical programs, said Ole Vesterqvist, senior director of Wyeth’s Biomarker Laboratory in Clinical Translational Medicine, in a statement.
Financial terms of the agreement were not released.